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Many patients undergoing day surgery are at low-risk of venous thromboembolic events. However, given
that pulmonary embolism is the most common preventable cause of hospital death, the risk-beneﬁt
proﬁle of thromboprophylaxis should be accurately balanced. In this narrative review, we will brieﬂy
discuss some topics of thromboprohylaxis in ambulatory surgical procedures: venous thromboembolic
risk stratiﬁcation, venous thromboembolic risk during laparoscopic surgery, use of antithrombotic drugs
in case of neuraxial anesthesia/analgesia, American College of Chest Physicians recommendations for
thromboprophylaxis.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Pulmonary embolism (PE) is the most common preventable
cause of hospital death.1 Without thromboprophylaxis, the inci-
dence of objectively conﬁrmed, hospital-acquired deep venous
thrombosis (DVT) is approximately 10–40% among general surgical
patients.2 The mortality, acute and long-term morbidities strongly
support effective preventive strategies at least for moderate-risk
and high-risk patients: a large number of randomized clinical trials
provide irrefutable evidence that primary pharmacological
thromboprophylaxis reduces DVT and PE.3,4 With respect to
complications of thromboprophylaxis, several data from meta-
analyses and blinded, randomized clinical trials have demonstrated
little or no increase in the rates of clinically important bleeding
with prophylactic doses of low-dose unfractionated heparin
(LDUH) or low-molecular-weight heparin (LMWH).1,4 For low-risk
patients, such as many patients undergoing day surgery, the risk-
beneﬁt proﬁle should be accurately balanced.
1. Thromboembolism risk stratiﬁcation
There are three general approaches to identify thromboembolic
risk.1 One approach considers the risk of venous thromboembolism
(VTE) in each patient, based on their individual predisposing factors
and the risk associated with their current illness or procedure.
Formal risk assessmentmodels (RAMs) for DVT have been proposed
to assist with this process.1,5 However, RAMs are not used routinely
by most clinicians and some experts – as described in the recent
American College of Chest Physicians (ACCP) guidelines onCircolo, Viale Borri 57, 21100
).
ciates Ltd. Published by Elsevier LtAntithrombotic and Thrombolytic Therapy – judges them of limited
value because they have not been adequately validated, there is
little formal understanding of how the various risk factors interact,
and do not simplify decision making.1 A second, simpliﬁed, risk
assessment approach stratiﬁes surgical patients assigning them to
one of the four VTE risk levels based on the type of operation
(minor, major), age (<40 years, 40–60 years, and >60 years), and
the presence of additional risk factors (such as cancer or previous
VTE).1 However, uncertainty about the inﬂuence of each factor on
overall risk, lack of deﬁnitions for minor and major surgery, and
arbitrary cut-offs for age and duration of surgery are major draw-
backs.1 A third approach – suggested by the panel experts of the
ACCP guideline – involves implementation of group-speciﬁc
thromboprophylaxis routinely for all patients who belong to each
of the major target groups, for example patients undergoing major
general surgery or major orthopedic surgery.1 While individualized
approach to thromboprophylaxis has not been subjected to
rigorous clinical evaluation, group risk assignment and thrombo-
prophylaxis are the basis for most randomized trials of thrombo-
prophylaxis.1 Moreover, a simpliﬁcation allows clinicians to readily
identify the general risk group for their patients and makes general
thromboprophylaxis recommendations.2. ACCP guideline and day-surgery procedures
The true incidence of DVT following minor minimal-access
surgery (MAS) is still unknown.6 Therefore, the current practice of
general surgeons with respect to DVT prophylaxis for MAS is
importantly variable.6 However, patients who undergo minor or
short-stay MAS are discharged from hospital on the day of surgery
and usually return to normal activities sooner than the followingd. All rights reserved.
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ﬁcation of the latest edition of the ACCP guideline, DVT risk is low,
less than 10% without thromboprophylaxis.1 For this group of
patients, the panel does not recommend to routinely administer
pharmacological thromboprophylaxis, but to force patients to an
early and ‘aggressive’ ambulation.1
Needless to say that a careful risk assessment of patient VTE risk
should be a current routine practice. In patients with a concomitant
VTE risk factor at the time of surgical procedure (such as a previous
episode of VTE), the use of pharmacological prophylaxis is
conversely recommended if bleeding risk is not increased.
3. Laparoscopic surgery
There is considerable uncertainty related to the thromboem-
bolic risk after laparoscopic procedures, and the use of thrombo-
prophylaxis is controversial.1,8,9 The rates of VTE following
laparoscopic procedures appear to be low.1 In a literature review
that included 153,832 laparoscopic cholecystectomies using
various types of thromboprophylaxis, the average rates of clinical
DVT, PE, and fatal PE were 0.03%, 0.06%, and 0.02%, respectively.10 In
a population-based study of 105,850 laparoscopic cholecystecto-
mies performed in California, the risk of symptomatic VTE within 3
months of the procedure was 0.2%, compared with 0.5% after open
cholecystectomy.11 Data from prospective study in which DVT were
routinely screened and objectively proven showed that the pooled
rate of asymptomatic DVT was 1.2% (18 of 1457 patients).1 Among
422 who do not receive thromboprophylaxis, only 1 was found to
have asymptomatic DVT.1
Despite no mechanical thromboprophylaxis option has been
studied in a large enough sample to determine if there is a reduc-
tion in the risk of death or PE, and in particular no trial has shown
that intermittent pneumatic compression (IPC) prevents DVT in
laparoscopic patients, the European Association for Endoscopic
Surgery has recommended that intraoperative IPC be used for all
prolonged laparoscopic procedures.1,9 In 2006, the Society of
American Gastrointestinal Endoscopic Surgeons recommended the
use of similar thromboprophylaxis options for laparoscopic proce-
dures as for the equivalent open surgical procedures.8 Conversely,
ACCP experts believe that the available evidence does not support
a recommendation for the routine use of thromboprophylaxis in
these patients: with anticoagulant thromboprophylaxis, the risk of
major bleeding may exceed the rate of thrombotic complications.1
Needless to say that patients who have additional VTE risk factors
can be considered for thromboprophylaxis with any of the
modalities currently recommended for surgical patients.1
4. Antithrombotic drugs and neuraxial anesthesia/analgesia
or peripheral nerve blocks
The risk of spinal or epidural hematoma, a potentially devas-
tating complication, may be increased with the concomitant use of
antithrombotic drugs, also after removal of an epidural catheter.1,12
Bleeding into the enclosed space of the spinal canal can produce
spinal cord ischemia and paraplegia. Therefore, even if the real
incidence of complication is unknown, cautious use of all antith-
rombotic medication in patients with neuraxial blockade is war-
ranted.1 ACCP guideline suggests that neuraxial anesthesia plus or
minus postoperative epidural analgesia can be used concomitantly
with prophylactic doses of LDUH or LMWH with appropriate
caution.1 In particular, insertion of the spinal needle or epidural
catheter should be delayed until the anticoagulant effect of the
medication is minimal: this is usually at least 8–12 h after
a subcutaneous dose of heparin or a twice-daily prophylactic dose
of LMWH, or at least 18 h after a once-daily prophylactic dose ofLMWH; anticoagulant thromboprophylaxis should be delayed if
a hemorrhagic aspirate (‘‘bloody tap’’) is encountered during the
initial spinal needle placement; removal of an epidural catheter
should be done when the anticoagulant effect of the thrombopro-
phylaxis is at a minimum (usually just before the next scheduled
subcutaneous injection); anticoagulant thromboprophylaxis
should be delayed for at least 2 h after spinal needle or epidural
catheter removal; although postoperative fondaparinux appears to
be safe in patients who have received a spinal anesthetic, until
deﬁnitive data will be available, ACCP guideline recommend that
fondaparinux not be administered along with continuous epidural
analgesia.1
The risk of clinically important bleeding associated with
superﬁcial nerve blocks appears to be so low that no precautions
other than those appropriate to the surgical procedure are
required.1 However, bleeding complications have been described
with the use of continuous deep nerve blocks. Bleeding may be
related to the experience of the anesthesiologist and may be
reduced by use of ultrasound-guided catheter placement. Until
further data become available, ACCP guideline recommends that
the above suggestions for neuraxial blocks also be considered for
deep peripheral nerve blocks.1Conﬂict of interest
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